Application 761149

Type
BLA
Sponsor
GENENTECH

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761149Enspryngsatralizumab-mwge351(a)Rx2026-07-01

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001ENSPRYNGSATRALIZUMABINJECTABLE;INJECTION120MG/MLNoNo

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
EnspryngSATRALIZUMABGenentech, Inc.64c156a4-9bad-4d45-a294-0733c141f47b2026-06-22Warnings, Adverse reactionsExact identifier
application number: BLA761149
ndc (product): 50242-007

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 6 matching rows.

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
50242-007EnspryngSatralizumabGenentech Inc.BLACurrent
50242-007EnspryngSatralizumabGenentech Inc.BLACurrent
50242-007EnspryngSatralizumabGenentech Inc.BLACurrent
50242-007EnspryngSatralizumabGenentech Inc.BLACurrent
50242-007EnspryngSatralizumabGenentech Inc.BLACurrent
50242-007EnspryngSatralizumabGenentech Inc.BLACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
72085SUPPL2022-09-15
72080SUPPL2022-09-15
72079SUPPL2022-09-15
67440SUPPL2021-05-07
67398SUPPL2021-05-04
64565ORIG2020-09-11
64288ORIG2020-08-17
64283ORIG2020-08-17